Open access
Open access
Powered by Google Translator Translator

Diabetes

ADA/EASD Consensus Report | Management of Hyperglycemia in Type 2 Diabetes, 2022.

26 Sep, 2022 | 12:11h | UTC

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) – Diabetes Care

News Release: ADA/EASD Consensus Update on Management of Hyperglycemia in Type 2 Diabetes – Report Published in Diabetes Care – American Diabetes Association

Commentary: ADA/EASD hyperglycemia management consensus update strengthens holistic care – medwire News

 


M-A | Association of gestational diabetes mellitus with cardiovascular and cerebrovascular diseases.

26 Sep, 2022 | 12:01h | UTC

Association of gestational diabetes mellitus with overall and type specific cardiovascular and cerebrovascular diseases: systematic review and meta-analysis – The BMJ

News Release: Diabetes in pregnancy linked to risk of cardiovascular and cerebrovascular disease – BMJ Newsroom

 

Commentary on Twitter

 


Cohort Study | Modifiable risk factors may reduce the risk of type 2 diabetes in patients with a history of gestational diabetes.

23 Sep, 2022 | 13:08h | UTC

Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study – The BMJ

News Release: Healthy lifestyle linked to 90% lower risk of diabetes in susceptible women – BMJ Newsroom

 

Commentary on Twitter

 


RCT | Insulin Glargine vs. Glimepiride vs. Sitagliptin vs. Liraglutide resulted in similar microvascular outcomes and death rates in patients with Type 2 diabetes not controlled with metformin.

22 Sep, 2022 | 13:20h | UTC

Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes – New England Journal of Medicine (link to abstract – $ for full-text)

Related Study: Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes – New England Journal of Medicine

News Release: Two popular diabetes drugs outperformed others in large clinical trial – National Institutes of Health

 


Study shows that the leading causes of hospitalization of adults with diabetes are changing.

22 Sep, 2022 | 13:08h | UTC

Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records – The Lancet Diabetes & Endocrinology

Commentaries:

The changing character of diabetes complications – The Lancet Diabetes & Endocrinology (free registration required)

Reasons for hospital admissions in people with type 2 diabetes are changing – MedicalXpress

 


RCT | Open-source automated insulin delivery in Type 1 Diabetes.

19 Sep, 2022 | 12:41h | UTC

Open-Source Automated Insulin Delivery in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Video summary: Open-Source Automated Insulin Delivery in Type 1 Diabetes – NEJM

Commentaries:

Open-Source AID Systems Can Improve Glycemic Control in Both Children and Adults with Type 1 Diabetes – Endocrinology Network

Automated Insulin Delivery Ups Time in Target Glucose Range in T1D – HealthDay

 


Cohort Study | Patients diagnosed with diabetes by oral glucose tolerance test without elevated HbA1c had similar cardiovascular and renal disease risks as those without diabetes.

15 Sep, 2022 | 13:12h | UTC

Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study – Circulation

Commentary: Patients diagnosed by OGTT without elevated HbA1c had similar CV, renal disease risks as those without diabetes – ACP Diabetes

 

Commentary on Twitter

 


Consensus recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice.

15 Sep, 2022 | 13:06h | UTC

Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice – Endocrine Reviews

 


USPSTF Statement | The current evidence is insufficient to recommend routine screening for prediabetes and type 2 diabetes in children and adolescents.

14 Sep, 2022 | 13:23h | UTC

Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: US Preventive Services Task Force Recommendation Statement – JAMA

Editorials:

Recommendations for Screening Children and Adolescents for Prediabetes and Type 2 Diabetes – JAMA

Broader Screening for Youth-Onset Type 2 Diabetes—We Just Are Not There Yet – JAMA Network Open

Evidence Report: Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Patient Page: Screening for Type 2 Diabetes in Children and Adolescents – JAMA

Author Interview: USPSTF Recommendation: Screening for Prediabetes and Diabetes in Children and Adolescents – JAMA

 


Cluster RCT | Tighter vs. less tight glycemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity.

13 Sep, 2022 | 13:21h | UTC

Tighter or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity: A stepped-wedge, cluster-randomised trial – PLOS Medicine

 


RCT | In youths with new-onset type 1 diabetes, intensive glucose control for 24 months with a closed-loop system did not help to preserve pancreatic function.

11 Sep, 2022 | 22:57h | UTC

Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

MedH researcher on new study on preserved insulin production in type 1 diabetes – Karolinska Institutet

Preservation of C-Peptide Secretion Examined in Youth With T1D – HealthDay

 

Commentary on Twitter (video summary)

 


A randomized crossover trial with 12 patients showed that a bihormonal “artificial pancreas” with closed-loop glucose control increases patients’ time on euglycemia after total pancreatectomy.

11 Sep, 2022 | 22:45h | UTC

Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Commentary: Novel Bihormonal Artificial Pancreas Beneficial After Pancreatectomy – HealthDay

 


Study shows bariatric surgery is more effective than lifestyle for type 2 diabetes remission.

8 Sep, 2022 | 14:27h | UTC

News Release: Bariatric surgery more effective than lifestyle for type 2 diabetes remission – Pennington Biomedical Research Center

Original Study: Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) – Diabetes Care

 


RCT | Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes.

7 Sep, 2022 | 12:30h | UTC

Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study – The Lancet Endocrinology (link to abstract – $ for full-text)

Commentary: ‘Artificial Pancreas’ Best in Poorly Controlled Type 1 Diabetes – Medscape (free registration required)

 

Commentary on Twitter

 


RCT | The effect of a liberal approach to glucose control in critically ill patients with type 2 diabetes.

1 Sep, 2022 | 11:37h | UTC

The Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A multicenter, parallel-group, open-label, randomized clinical trial – American Journal of Respiratory and Critical Care Medicine (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 


#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.

30 Aug, 2022 | 12:14h | UTC

News Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology

Original Study: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER – Nature Medicine

Related:

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

 


Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.

30 Aug, 2022 | 11:59h | UTC

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)

Related: Meta-analysis of randomized trials: GLP1 receptor agonists increase the risk of gallbladder and biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

 


#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

29 Aug, 2022 | 12:36h | UTC

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology

Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

 

Commentary on Twitter

 


Update on the management of diabetes in long-term care facilities.

26 Aug, 2022 | 13:23h | UTC

Update on the management of diabetes in long-term care facilities – BMJ Open Diabetes Research & Care

 


Randomized Crossover Trial | In patients with diabetic neuropathic pain, amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective.

25 Aug, 2022 | 12:14h | UTC

Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial – The Lancet

 


Study Commentary | Is the evidence strong for spinal cord stimulation for diabetic neuropathy? Not all experts agree.

25 Aug, 2022 | 11:52h | UTC

Is the Evidence Strong for Spinal Cord Stimulation for Diabetic Neuropathy? Not All Experts Agree – Neurology Today

Original Study: RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy

 


Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses.

24 Aug, 2022 | 14:17h | UTC

News Release: Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses – Cell Press

Original Study: Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance – Cell

Commentary: Expert reaction to study looking at the effect of non-nutritive sweeteners on human microbiomes and glycaemic levels – Science Media Centre

 

Commentary on Twitter

 


Guideline | Management of adults with diabetes on dialysis.

23 Aug, 2022 | 13:16h | UTC

Management of adults with diabetes on dialysis – Joint British Diabetes Societies for Inpatient Care (PDF)

News Release: Latest JBDS dialysis guideline published – Diabetes Times

 


RCT | A lower glycemic criteria in not better than higher glycemic criteria for the diagnosis of gestational diabetes.

18 Aug, 2022 | 13:04h | UTC

Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Pros and cons with lower vs higher threshold for gestational diabetes diagnosis – medwire News

 

Commentary on Twitter (thread – click for more)

 


M-A of randomized trials | Effectiveness of exercise intervention during pregnancy on high-risk women for gestational diabetes mellitus prevention.

16 Aug, 2022 | 13:40h | UTC

Effectiveness of exercise intervention during pregnancy on high-risk women for gestational diabetes mellitus prevention: A meta-analysis of published RCTs – PLOS One

 


Stay Updated in Your Specialty

No spam, just news.